Evaluating the Efficacy of Fecal Occult Blood Test and Tumor Marker Combined Screening for Colorectal Cancer

Objective:To analyze the screening effectiveness of combining the fecal occult blood test with tumor marker detection for colorectal cancer.Methods:A total of thirty patients with colorectal cancer and thirty patients with benign colon hyperplasia who received treatment from January 2020 to January 2023 were selected.These patients were assigned to the observation group and the control group,respectively.All patients in both groups underwent both fecal occult blood tests and tumor marker detection.The levels of tumor markers between the two groups were compared,the tumor marker levels in different stages were assessed within the observation group,and the positive detection rates for single detection and combined detection were compared.Results:The levels of various tumor markers in the observation group were significantly higher than those in the control group(P<0.05).Furthermore,as the Duke stage increased within the observation group,the levels of various tumor markers also increased(P<0.05).The positive detection rate of the combined test was notably higher than that of single detection(P<0.05).Conclusion:Combining the fecal occult blood test with tumor marker detection in colorectal cancer screening can significantly improve the overall detection rate.

Effects of Shenqi Fuzheng injection combined with chemotherapy on peripheral blood, immune function and tumor markers in patients with breast cancer

Objective: To investigate the effects of Shenqi Fuzheng Injection Combined with chemotherapy on peripheral blood, immune function and tumor markers in patients with breast cancer. Methods: A total of 92 cases of breast cancer treated by modified radical mastectomy in our hospital from January 2017 to December 2017 were selected as the research subjects and were randomly divided into 46 cases in the observation group and 46 cases in the control group. The patients in the control group began chemotherapy after 2 weeks of surgery, and the observation group was given Shenqi Fuzheng Injection on the basis of the control group. The levels of leukocyte, platelet, hemoglobin, T cell subgroup, carcinoembryonic antigen (CEA), cancer antigen 153 (CA153) and carbohydrate antigen 125 (CA125) were measured and compared of patients in two groups. Results: Before treatment, there was no significant difference in white blood cell, platelet and hemoglobin between the two groups. After treatment, the white blood cells, platelets and hemoglobin in the observation group were (3.56±0.10)×109/L, (137.47±23.58)×109/L, (116.72±15.75) g/L, and the white cells, platelets and hemoglobin in the control group were (2.85±0.18)×109/L, (126.76±21.34)×109/L, (103.36±20.51) g/L, respectively, all the indexes decreased than before treatment, moreover the decrease of control group is more obvious than observation group, and the difference was statistically significant. Before treatment, there was no significant difference in CD3+, CD4+, CD8+and CD4+/CD8+between the two groups. After treatment, the CD3+, CD4+and CD4+/CD8+in the observation group were (58.02±12.77)%, (50.79±7.45)% and (2.13±0.69), which were significantly higher than those before the treatment, and increased compared with the control group in the corresponding period, the difference was statistically significant. Before treatment, there was no significant difference in CEA, CA153 and CA125 between the two groups. After treatment, the CEA, CA153 and CA125 of the observation group were (16.70±3.71) μg/L, (13.11±3.70) U/mL and (11.25±1.73) U/mL, and in the control group they were (21.71±4.24) μg/L, (20.31±4.21) U/mL and (17.78±2.36) U/mL, respectively, the CEA, CA153 and CA125 in two groups were all lower than those before treatment, and the indexes of the observation group were decreased more significantly than those of the control group, the differences were statistically significant. Conclusion: Shenqi Fuzheng Injection Combined with chemotherapy in peripheral blood and immune function significantly improved in patients with breast cancer, and a significant decrease in the level of tumor markers.

Effect of Shenqi Fuzheng Injection combined with chemotherapy on peripheral blood cell level, tumor markers and immune function in patients with gastric cancer

Objective:To investigate the effects of Shenqi Fuzheng Injection combined with chemotherapy on peripheral blood cell level, tumor markers and immune function in patients with gastric cancer.Methods: Eighty patients with gastric cancer admitted to our hospital from May 2016 to October 2017 were selected as the research object and randomly divided into observation group and control group, 40 cases in each group. Control group was treated by DCF chemotherapy, while the observation group by Shenqi Fuzheng Injection based on the DCF chemotherapy. The levels of peripheral blood cells, tumor markers and immune function indexes in both groups were detected and compared before and after treatment.Results: There were no significant differences in serum RBC, WBC, PLT, Hb, NSE, CYFRA21-1, CA199, CEA, CD3+, CD4+, CD8+ and CD4+/CD8+ levels before treatment in both groups. Compared with the pretreatment group, the levels of RBC, WBC, PLT and Hb in both groups decreased to some extent after treatment, and the levels in the observation group were significantly higher than those in the control group;Compared with the same group before treatment, the levels of NSE, CYFRA21-1, CA199 and CEA in the two groups were significantly decreased, and the observation group was significantly lower than the control group;CD3+, CD4+, CD4+/CD8+ levels in control group and observation group increased to some extent after treatment, and the levels in observation group were significantly higher than those in control group. The levels of CD8+ in both groups after treatment were significantly lower than those before treatment, and the observation group was significantly lower than the control group after treatment. The above data for statistical analysis had significant differences.Conclusions: Shenqi Fuzheng injection combined with chemotherapy helps to clear and kill cancer cells, enhance immunity and reduce hematological toxicity after chemotherapy, which can be used as an adjuvant chemotherapy for gastric cancer.

Influence of blood glucose fluctuations on chemotherapy efficacy and safety in type 2 diabetes mellitus patients complicated with lung carcinoma

BACKGROUND Patients with type 2 diabetes mellitus(T2DM)have large fluctuations in blood glucose(BG),abnormal metabolic function and low immunity to varying degrees,which increases the risk of malignant tumor diseases and affects the efficacy of tumor chemotherapy.Controlling hyperglycemia may have important therapeutic implications for cancer patients.AIM To clarify the influence of BG fluctuations on chemotherapy efficacy and safety in T2DM patients complicated with lung carcinoma(LC).METHODS The clinical data of 60 T2DM+LC patients who presented to the First Affiliated Hospital of Ningbo University between January 2019 and January 2021 were retrospectively analyzed.All patients underwent chemotherapy and were grouped as a control group(CG;normal BG fluctuation with a mean fluctuation<3.9 mmol/L)and an observation group(OG;high BG fluctuation with a mean fluctuation≥3.9 mmol/L)based on their BG fluctuations,with 30 cases each.BGrelated indices,tumor markers,serum inflammatory cytokines and adverse reactions were comparatively analyzed.Pearson correlation analysis was performed to analyze the correlation between BG fluctuations and tumor markers.RESULTS The fasting blood glucose and 2-hour postprandial blood glucose levels in the OG were notably elevated compared with those in the CG,together with markedly higher mean amplitude of glycemic excursions(MAGE),mean of daily differences,largest amplitude of glycemic excursions and standard deviation of blood glucose(P<0.05).In addition,the OG exhibited evidently higher levels of carbohydrate antigen 19-9,carbohydrate antigen 125,carcinoembryonic antigen,neuron-specific enolase,cytokeratin 19,tumor necrosis factor-α,interleukin-6,and highsensitivity C-reactive protein than the CG(P<0.05).Pearson analysis revealed a positive association of MAGE with serum tumor markers.The incidence of adverse reactions was significantly higher in the OG than in the CG(P<0.05).CONCLUSION The greater the BG fluctuation in LC patients after chemotherapy,the more unfavorable the therapeutic effect of chemotherapy;the higher the level of tumor markers and inflammatory cytokines,the more adverse reactions the patient experiences.

Combined measurement of serum tumor markers in patients with hepatocellular carcinoma

ＣｏｍｂｉｎｅｄｍｅａｓｕｒｅｍｅｎｔｏｆｓｅｒｕｍｔｕｍｏｒｍａｒｋｅｒｓｉｎｐａｔｉｅｎｔｓｗｉｔｈｈｅｐａｔｏｃｅｌｕｌａｒｃａｒｃｉｎｏｍａＣＡＩＷｅｎＸｉｕ，ＺＨＥＮＧＨｕｉ，ＳＨＥＮＧＪｉａｎａｎｄＹＥＱｉｎｇＬｉｎＳｕｂｊｅｃｔｈ...

土鳖虫化学成分和药理作用的研究进展及其质量标志物(Q-Marker)的预测分析

土鳖虫是我国传统中药,分布于河南、河北、江苏、湖南等地,具有破血逐瘀、续筋接骨的功效。土鳖虫中化学成分种类丰富,主要包括蛋白质及多肽类、氨基酸类、脂肪酸类、生物碱、无机元素、核苷类等。现代药理研究表明,土鳖虫具备抗凝血并防止血栓形成、调节血脂的作用,此外,还具有抗肿瘤、抗炎、增强免疫力、抗氧化等作用。近年来,土鳖虫等动物类中药在临床应用方面备受关注。本文对土鳖虫化学成分和药理作用的研究现状进行总结,在此基础上分析功效作用与化学成分之间的联系,发现蛋白质及多肽类成分与抗凝血、调血脂作用关联紧密,生物碱类成分与抗菌抗炎作用相关。并从传统功效、现代药理、化学成分可测性、中药配伍等角度预测分析其质量标志物(quality marker,Q-Marker),初步确定土鳖虫活性肽组分、纤溶活性蛋白、脂肪酸类成分、生物碱、核苷类成分等可作为其质量标志物。中药质量标志物的研究为鉴定土鳖虫的真假优劣提供依据,也为后续开发土鳖虫新剂型、制定质量标准提供理论基础。

Expression of CD44v6 gene in normal human peripheral blood

AIM: To investigate if CD44v6 could be used as a molecular marker of cancer progression and metastasis through the detection of CD44v6 gene expression in normal human peripheral blood.METHODS: RNA was extracted from the peripheral blood mononuclear cells of 50 healthy donors, the expression of CD44v6 was investigated using reverse transcriptasepolymerase chain reaction (RT-PCR).RESULTS: CD44v6 mRNA was detected in 58% of healthy volunteers under the proper controls.CONCLUSION: Our results suggest that the measurement of CD44v6 expression in peripheral blood by RT-PCR is not suitable for detection of circulating tumor cells.

Application of proteome technology in screening biomarkers associated with gastric cancer

Objective: To initially explore the application of proteome technologies in study of serum, to establish two-dimen-sional gel electrophoresis (2-DE) profiles of human gastric cancer serum and paired normal serum, and to screen and identify differentially expressed proteins in poorly-differentiated gastric cancer serum and paired normal serum, in which try to find out significant biomarker candidates for gastric cancer. Methods: 2-DE was adopted to separate the total proteins of poorly-differentiated gastric cancer serum and paired normal serum. After staining and analyzing by ImageMaster 2D Elite software, the differentially expressed proteins were identified by matrix-assisted laser desorption/ionization-time of flight- mass spectrometry (MALDI-TOF-MS). Results: 2-DE serum profiles with high resolution were obtained. Five protein spots were found as differentially-expressed proteins and identified as Serpin B6 (Placental thrombin inhibitor) Cytoplasmic antiproteinase (CAP) (Protease inhibitor6) (PI-6), Septin-1 (LARP) (Serologically defined breast cancer antigen NY-BR-24), Kallikrein-6 precursor (Protease M) (Neurosin) (Zyme) (SP59), Hemoglobin beta chain, Hemoglobin beta chain and Beta-defensin 108 precursor (Beta-defensin 8) (DEFB-8). Conclusion: The differential proteins were demonstrated to present in poorly-differentiated gastric cancer serum and paired normal serum. The molecular biomarkers associated with poorly differentiated gastric cancer could be possibly identified by the high throughput screening proteome technology.

肺瘤消积方联合吉非替尼治疗痰瘀互结型晚期非小细胞肺癌的临床疗效

目的探讨肺瘤消积方联合吉非替尼治疗痰瘀互结型晚期非小细胞肺癌(NSCLC)的临床疗效及对血清肿瘤标志物和炎性因子水平的影响。方法选取2019年2月—2021年2月于我院就诊的痰瘀互结型晚期NSCLC患者100例,根据随机数字表法分为对照组和治疗组(n=50)。对照组患者口服吉非替尼片,治疗组患者在对照组的基础上加用肺瘤消积方,以21 d为1个治疗周期,两组患者均治疗4周期。对比分析两组血清肿瘤标志物和炎性因子水平、生活质量评分、无进展生存期(PFS)、中医症状分级、临床疗效、不良反应。结果治疗后,两组细胞角质蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、白细胞介素-1(IL-1)、IL-6、肿瘤坏死因子-α(TNF-α)水平以及癌症患者生命质量测定量表(QLQ-C30)评分均低于治疗前,且治疗组低于对照组(P<0.05);治疗组PFS显著长于对照组(P<0.05);两组中医症状分级均显著改善,且治疗组优于对照组(P<0.05);治疗组客观缓解率(ORR)、疾病控制率(DCR)(68.00%、84.00%)均显著高于对照组(42.00%、62.00%)(P<0.05);治疗组皮肤反应、腹泻总发生率(22.00%、50.00%)均显著低于对照组(42.00%、74.00%)(P<0.05)。结论肺瘤消积方联合吉非替尼治疗痰瘀互结型晚期NSCLC患者疗效显著,可有效降低患者血清CYFRA21-1、CA19-9、CEA、IL-1、IL-6、TNF-α水平,改善患者病情,且安全性较高。

外周血炎症指数与乳腺癌腋窝淋巴结转移的相关性分析

目的 探讨外周血炎症相关指数与乳腺癌腋窝淋巴结转移的相关性。方法 回顾性收集2018年1月—2023年8月就诊于兰州大学第二医院浸润性乳腺癌患者的首次就诊临床资料,计算外周血相关炎症指数,分析各项指数与腋窝淋巴结转移的相关性。结果 共收集了328例患者的临床资料,单因素分析显示,体重指数、肿瘤直径、癌胚抗原、癌胚抗原125、系统炎症反应指数和泛免疫炎症值在腋窝淋巴结转移组和非腋窝淋巴结转移组之间差异有统计学意义(P<0.05)。多因素分析发现肿瘤直径、泛免疫炎症值、系统炎症反应指数、体重指数、组织学分级Ⅲ级和癌胚抗原125是腋窝淋巴结转移的独立危险因素。受试者操作特征曲线中泛免疫炎症值的曲线下面积为0.634,最佳临界值为110.37。系统炎症反应指数的曲线下面积为0.639,最佳临界值为0.554。结论 泛免疫炎症值和系统炎症反应指数与浸润性乳腺癌腋窝淋巴结转移相关,可以作为乳腺癌腋窝淋巴结转移的潜在预测指标。

痛风患者血清糖类抗原72-4水平及其与尿酸水平的关系分析

目的分析痛风患者血清糖类抗原72-4(CA72-4)水平,并探讨其与血尿酸水平的关系。方法回顾性选取2020年1月至2022年12月在中国人民解放军联勤保障部队第九〇三医院治疗的痛风患者120例,为痛风组。另择同期来院体检的健康体检者52名为对照组。两组均清晨空腹抽取肘静脉血,采用电化学发光法测定血清CA72-4水平,采用全自动生化分析仪测定血清尿酸水平。比较两组血清CA72-4、尿酸水平;分析痛风组患者血清CA72-4水平与尿酸的相关性及发生痛风的危险因素。结果痛风组患者血清CA72-4、尿酸水平均高于对照组[(5.76±1.39)U/mL比(1.21±0.37)U/mL、(748.29±75.41)μmol/L比(321.20±34.52)μmol/L],差异均有统计学意义(均P<0.05)。Pearson相关分析显示,痛风组患者血清CA72-4水平与尿酸呈正相关(r=0.572,P<0.05)。多因素logistic回归分析显示,高血清CA72-4、尿酸、ESR和hs-CRP水平均是痛风的危险因素(均P<0.05)。结论痛风患者血清CA72-4水平明显升高,且与尿酸水平呈正相关。血清CA72-4水平或可作为痛风患者早期诊断的辅助指标。

胰腺肿瘤伴血糖异常对肿瘤标志物的影响分析

目的 探讨胰腺肿瘤伴血糖异常患者检验肿瘤标志物指标的影响。方法 选取80例胰腺肿瘤患者,其中良性胰腺肿瘤患者40例(血糖正常患者20例,血糖异常患者20例),恶性胰腺肿瘤患者40例(血糖正常患者20例,血糖异常患者20例)。两组患者均开展肿瘤标志物检查。比较良性胰腺肿瘤患者与恶性胰腺癌患者以及良性肿瘤、恶性肿瘤患者中血糖正常和血糖异常患者的糖类抗原199(CA199)、癌胚抗原(CEA)、甲胎蛋白(AFP)、糖类抗原125(CA125)、糖类抗原153(CA153)水平。结果 恶性胰腺肿瘤患者CA199(76.37±10.16)U/ml、CEA(26.13±6.38)ng/ml、AFP(22.32±7.19)ng/ml、CA125(63.85±12.11)U/ml、CA153(45.96±10.27)U/ml均明显高于良性胰腺肿瘤患者的(13.20±2.11)U/ml、(2.65±0.35)ng/ml、(3.37±0.13)ng/ml、(13.79±2.02)U/ml、(7.92±1.21)U/ml(P<0.05)。恶性胰腺肿瘤血糖异常患者的CA199(86.41±10.19)U/ml、CEA(30.63±6.26)ng/ml、AFP(28.13±8.27)ng/ml、CA125(68.77±3.10)U/ml、CA153(50.16±4.24)U/ml均高于血糖正常患者的(66.33±10.14)U/ml、(21.63±7.22)ng/ml、(16.51±7.24)ng/ml、(58.93±3.02)U/ml、(41.76±4.21)U/ml(P<0.05)。良性胰腺肿瘤血糖正常和血糖异常患者的CA199、CEA、AFP、CA125、CA153水平比较,无统计学差异(P>0.05)。结论 对于胰腺肿瘤患者来讲,血糖异常对肿瘤标志物指标有明显影响,应予以重点关注,合理控制血糖,从而为疾病的进一步治疗奠定良好条件。

Early diagnostic strategies for colorectal cancer

At present,cancer is still an important factor threatening human health.Colorectal cancer(CRC)is one of the top three most common cancers worldwide and one of the deadliest malignancies in humans.The latest data showed that CRC incidence and mortality rank third and second,respectively,among global malignancies.Early and accurate diagnosis is crucial to reduce the morbidity,mortality and improve survival of patients with CRC,but the current early diagnostic methods have limitations.The effectiveness and compliance of diagnostic methods have a certain impact on whether people choose screening.In this editorial,we explore strategies for the early diagnosis of CRC,including stool-based,blood-based,direct visualization,and imaging examinations.

粪便隐血及肿瘤标志物联合检验在诊断结直肠癌中的作用及结果分析

目的 探讨粪便隐血及肿瘤标志物联合检验在诊断结直肠癌中的应用价值。方法 选取2020年1月-2022年12月广州市番禺区康复医院接诊的疑似结直肠癌患者100例,对所有就诊患者进行粪便隐血、肿瘤标志物检验及联合检验,对检验结果进行分析。结果 确诊者95例,确诊结直肠癌患者的CA24-2、CA19-9、CEA水平相比未确诊人群均明显更高(P<0.05);联合检测检出率、灵敏度、特异性分别为98.00%、98.41%、97.30%,联合检验的诊断效能明显高于单一检验方式(P<0.05)。结论 粪便隐血及肿瘤标志物联合检验方式相比单一检验,对结直肠癌的诊断效果更高,值得在临床中推广应用。

肺癌恶性胸腔积液患者外周血中肿瘤标志物Hsp90α的表达水平及其预后评估

目的分析肺癌恶性胸腔积液患者外周血中肿瘤标志物热休克蛋白90α(Hsp90α)的表达水平及其对预后的评估作用。方法选取安徽省阜阳市人民医院2018年1月至2021年1月收治的80例肺癌合并恶性胸腔积液患者作为A组,另选取同期安徽省阜阳市人民医院收治的80例良性胸腔积液患者作为B组及体检的80名健康者作为C组纳入研究。采用酶联免疫吸附试验检测三组外周血中肿瘤标志物Hsp90α表达水平。Kaplan-Meier法评估Hsp90α的表达与肺癌恶性胸腔积液患者预后的关系。结果三组外周血中肿瘤标志物Hsp90α表达比较,差异有统计学意义(P<0.05)。其中A组、B组外周血中肿瘤标志物Hsp90α表达高于C组,A组高于B组,差异有统计学意义(P<0.05)。不同年龄、性别、肿瘤直径、临床分期、淋巴结转移、病理分级及是否吸烟的肺癌恶性胸腔积液患者外周血中肿瘤标志物Hsp90α表达水平比较,差异无统计学意义(P>0.05)。Hsp90α高表达组的OS和RFS低于低表达组(P<0.05)。结论肺癌恶性胸腔积液患者外周血中肿瘤标志物Hsp90α水平明显升高,且其水平与预后生存状况具有紧密相关性,可将其作为肺癌恶性胸腔积液患者诊断、预后的重要指标。

血清肿瘤标志物联合阴道超声血流参数鉴别卵巢浆液性囊性腺瘤与囊腺癌的诊断价值

目的探讨血清肿瘤标志物糖类抗原125(CA125)、人附睾蛋白4(HE4)联合阴道超声血流参数鉴别卵巢浆液性囊性腺瘤与浆液性囊腺癌的诊断价值。方法选取76例卵巢浆液性囊性腺瘤患者与73例卵巢浆液性囊腺癌患者,分别作为卵巢浆液性囊性腺瘤组、卵巢浆液性囊腺癌组。检测所有患者CA125、HE4水平,阴道超声检查记录阴道超声血流参数相关指标;Logistic回归分析卵巢浆液性囊腺癌的相关因素;采用受试者工作特征曲线(ROC)分析CA125、HE4联合阴道超声血流参数鉴别卵巢浆液性囊性腺瘤与浆液性囊腺癌的诊断价值。结果卵巢浆液性囊腺癌组血清CA125、HE4水平高于卵巢浆液性囊性腺瘤组,差异有统计学意义(P<0.05)。卵巢浆液性囊腺癌组阻力指数(RI)低于卵巢浆液性囊性腺瘤组,舒张末期流速(EDV)高于卵巢浆液性囊性腺瘤组,差异有统计学意义(P<0.05)。多因素logistics回归分析显示CA125、HE4、EDV是发生卵巢浆液性囊腺癌的危险因素,RI是发生卵巢浆液性囊腺癌的保护因素(P<0.05)。ROC结果显示CA125、HE4、RI、EDV及联合诊断的曲线下面积(AUC)为0.863、0.815、0.835、0.899、0.965;联合诊断优于单独诊断(Z=3.595、4.736、4.089、2.410,P<0.05)。结论血清肿瘤标志物CA125、HE4联合阴道超声血流参数鉴别卵巢浆液性囊性腺瘤与浆液性囊腺癌具有较高的诊断效能。

粪便隐血试验与肿瘤标志物联合检测在结直肠癌诊断中的应用价值

目的:探讨粪便隐血试验与肿瘤标志物联合检测在结直肠癌诊断中的应用价值。方法:选取2021年9月—2023年10月高青县妇幼保健院收治的110例疑似结直肠癌患者作为研究对象,均接受粪便隐血试验、肿瘤标志物检测、结肠镜检查,以结肠镜检查诊断结果作为“金标准”,分析粪便隐血试验、肿瘤标志物检测以及联合检测诊断结直肠癌的灵敏度、特异度、阳性预测值、阴性预测值及准确率。结果:结肠镜检查结果显示,110例受试者中,确诊结直肠癌92例。粪便隐血试验、肿瘤标志物检测以及联合检测诊断结直肠癌的灵敏度、阴性预测值、准确率比较,联合检测>粪便隐血试验>肿瘤标志物检测,差异有统计学意义(P<0.05);粪便隐血试验、肿瘤标志物检测以及联合检测诊断结直肠癌的特异度、阳性预测值比较,差异无统计学意义(P>0.05)。结论:粪便隐血试验与肿瘤标志物联合检测能够提高结直肠癌的诊断灵敏度、阴性预测值及准确率,可作为结直肠癌早期筛查的有效辅助方法,为临床诊治工作提供科学参考。

解毒舒肝活血方对原发性肝癌微波消融术后的疗效及对患者肿瘤标志物、免疫功能的影响

目的:评价原发性肝癌(PLC)患者微波消融术后应用解毒舒肝活血方治疗的疗效,观察患者肿瘤标志物及免疫相关指标变化。方法:选择我院2021年1月~2023年12月的120例微波消融术的原发性肝癌患者作为研究对象,采用随机数字表法分为两组,对照组60例术后给予常规保肝降酶、抗病毒等治疗,观察组60例在此基础上给予解毒舒肝活血方治疗,比较两组疗效及治疗前、后血清甲胎蛋白(AFP)、甲胎蛋白异质体L3(AFP-L3)、CD3^(+)、CD4^(+)、CD8^(+)细胞绝对值及CD4^(+)/CD8^(+)比值。结果:观察组ORR、DCR分别为65.00%、91.67%,均高于对照组的41.67%、81.67%(P<0.05)。治疗后两组AFP、AFP-L3水平均低于治疗前(P<0.05)。观察组治疗后AFP、AFP-L3水平均低于对照组(P<0.05)。治疗后观察组CD3^(+)、CD4^(+)细胞绝对值及CD4^(+)/CD8^(+)比值均高于治疗前,CD8^(+)绝对值低于治疗前(P<0.05)。观察组治疗后CD3^(+)、CD4^(+)细胞绝对值及CD4^(+)/CD8^(+)比值均高于对照组,CD8^(+)绝对值低于对照组(P<0.05)。结论:解毒舒肝活血方可在一定程度上改善PLC患者微波消融术后的细胞免疫功能,降低肿瘤标志物水平,提高近期疗效。

2型糖尿病患者血糖控制前后肿瘤标志物的动态变化研究

目的观察血糖控制前后2型糖尿病患者肿瘤标志物的变化,为2型糖尿病的诊疗提供一定参考依据。方法纳入平顶山市第一人民医院2021年1月至2023年6月收治的78例2型糖尿病患者为研究样本。所有患者入院后均接受常规血糖控制治疗,治疗6个月后对比血糖控制前后肿瘤标志物血清癌胚抗原(CEA)、糖链抗原19-9(CA19-9)、糖链抗原15-3(CA15-3)、糖链抗原72-4(CA72-4)、甲胎蛋白(AFP);随访3个月后对比血糖控制治疗后血糖控制达标者与未达标者者直肠区域、乳腺区域、胰腺区域、肝内肿瘤发生率。结果78例患者血糖控制后CEA、CA19-9、CA15-3、CA72-4、AFP均低于血糖控制前,差异有统计学意义(P<0.05);经上述检查发现治疗后血糖控制达标50例、未达标28例,达标者肿瘤患病患病率(10.00%)低于未达标者(50.00%),差异有统计学意义(P<0.05)。结论2型糖尿病患者血糖控制后,CEA、CA19-9、CA15-3、CA72-4、AFP呈现由高至低的变化,可为直肠区域、乳腺区域、胰腺区域、肝内肿瘤诊疗提供一定信息,建议2型糖尿病患者定期复查。

兔VX2肿瘤的离体培养及有关生物学特性

目的:在体外分离纯化VX2肿瘤细胞,观察其生物学特性.方法:采用组织块法和消化法结合对兔VX2肿瘤进行原代培养,体外传代观察,传代40次并对培养细胞进行形态学观察、细胞周期检查、核型分析、兔及裸鼠移植.结果:纯化的兔VX2肿瘤细胞形态一致,呈圆形、多角形的上皮细胞,体积小,核浆比倒置,体外连续培养8mo,传代50次以上,细胞倍增时间为26.4h,细胞周期测定G1期为74.61%,G2期为7.78%,S期为17.6%.染色体为亚三倍体核型,众数为60条.高细胞浓度可保证同种移植成瘤率,裸鼠移植可成瘤,无支原体污染.结论:兔VX2肿瘤细胞系来源于Shope病毒致乳头瘤恶变形成的鳞状上皮细胞恶性肿瘤,目前已经纯化,可应用于进一步肿瘤实验研究.